The Pharmacovigilance Program of India (PvPI) is a national initiative launched by the Government of India to ensure the safety of medicines used by the Indian population. It aims to monitor, detect, assess, and prevent adverse drug reactions (ADRs) and ensure that medicines available in the market are safe and effective for public use.
PvPI was launched in 2010 under the Ministry of Health and Family Welfare (MoHFW) and is coordinated by the Indian Pharmacopoeia Commission (IPC). Since its inception, PvPI has significantly contributed to enhancing drug safety, public health, and patient safety in India.
Activities
As of 2018 there were 250 centers around India capable of responding to reports of serious adverse reactions. One of the challenges of the organization is training doctors and hospitals to report adverse drug reactions when patients have them. The Pharmacovigilance Program makes these reports itself, but ideally, such reports could originate from any clinic. The Pharmacovigilance Programme seeks to encourage a culture and social expectation of reporting drug problems.
Early Efforts in Pharmacovigilance in India
Before the formal establishment of PvPI, India participated in global pharmacovigilance initiatives. Some of the key milestones were:
- 1997: India became a member of the WHO Programme for International Drug Monitoring (WHO-PIDM), coordinated by the Uppsala Monitoring Centre (UMC), Sweden.
- 2002: The National Pharmacovigilance Program (NPP) was initiated under the Central Drugs Standard Control Organization (CDSCO) with the World Health Organization (WHO) support.
- 2004: NPP was officially launched with two centers: the South-West zonal center (Bangalore) and the North-East zonal center (Delhi).
- 2005: The Schedule Y of the Drugs and Cosmetics Act, 1940, was amended to include pharmacovigilance requirements in clinical trials.
- 2009: Due to ineffective reporting and lack of awareness, the NPP was reviewed for improvements.
Establishment of the Pharmacovigilance Programme of India (PvPI)
Given the limitations of the NPP, the Pharmacovigilance Programme of India (PvPI) was formally launched in July 2010 by the Ministry of Health and Family Welfare (MoHFW), Government of India.
Key Features of PvPI (2010-Present)
- National Coordination Centre (NCC): Initially, the PvPI was managed by the All India Institute of Medical Sciences (AIIMS), New Delhi. In 2011, the Indian Pharmacopoeia Commission (IPC), Ghaziabad, was designated as the NCC for PvPI.
- Expansion of ADR Monitoring Centers (AMCs): PvPI started with 22 AMCs across India. The number has grown significantly, with over 600 AMCs now actively reporting ADRs.
- Integration with Global PV Systems: India submitted its first Individual Case Safety Report (ICSR) to the UMC in 2011. Since then, India has become one of the leading contributors of ADR data to the WHO global database (VigiBase).
- PvPI Mobile App & Helpline: To promote ADR reporting, PvPI launched a mobile app and a toll-free helpline (1800-180-3024) in 2017.
- Collaboration with Regulatory Authorities: PvPI provides data to CDSCO, which helps in regulatory decisions such as drug withdrawals, black box warnings (A Black Box Warning (or Boxed Warning) is the strictest warning issued by the U.S. Food and Drug Administration (FDA) for prescription drugs. It is designed to alert healthcare professionals and patients about serious or life-threatening risks associated with the use of a medication.), and label modifications.
- Integration with Materiovigilance & Haemovigilance: Materiovigilance Programme of India (MvPI) was launched in 2015 to monitor medical device-related adverse events. Haemovigilance Programme of India (HvPI) was initiated in 2012 to track blood transfusion-related reactions.
1. Objectives of PvPI
The core objectives of the Pharmacovigilance Program of India include:
- Monitoring ADRs: Detect, report, and assess adverse drug reactions in the Indian population.
- Promoting the safe use of medicines: Minimize the risks associated with the use of medicines by identifying safety issues early.
- Generating evidence on drug safety: Gather real-world data on the safety of medicines used in the country.
- Risk assessment and management: Provide regulatory recommendations and interventions to prevent adverse effects and ensure drug safety.
- Raising awareness: Educate healthcare professionals and the public on the importance of reporting ADRs and pharmacovigilance practices.
2. Organizational Structure
a) Indian Pharmacopoeia Commission (IPC): The Indian Pharmacopoeia Commission (IPC) was designated as the National Coordination Centre (NCC) for PvPI in 2011. IPC is responsible for overseeing the collection and analysis of adverse drug reaction reports in India, and it coordinates with stakeholders such as healthcare professionals, pharmaceutical companies, regulatory bodies, and consumers.
b) National Coordination Centre (NCC) The NCC plays a pivotal role in:
- Developing standard operating procedures (SOPs) for the collection, processing, and analysis of ADRs.
- Coordinating with regional and peripheral ADR monitoring centers (AMCs).
- Disseminating drug safety information to regulatory authorities like the Central Drugs Standard Control Organization (CDSCO) and other stakeholders.
- Training and capacity building for pharmacovigilance professionals.
c) Adverse Drug Reaction Monitoring Centers (AMCs): PvPI operates through a network of Adverse Drug Reaction Monitoring Centers (AMCs). These AMCs are established in medical colleges and hospitals across India and are tasked with collecting ADR reports from healthcare providers and patients. As of 2024, there are more than 600 AMCs across the country, making PvPI one of the largest pharmacovigilance networks globally.
d) Central Drugs Standard Control Organization (CDSCO): The CDSCO is India’s national regulatory body for pharmaceuticals and is an essential partner in the PvPI. It uses the safety data generated by PvPI to:
- Make regulatory decisions regarding drug safety.
- Implement risk mitigation measures such as issuing safety alerts, revising product labels, or withdrawing unsafe medicines from the market.
3. ADR Reporting and Analysis
PvPI relies heavily on spontaneous reporting from healthcare professionals (doctors, pharmacists, nurses) and consumers (patients, caregivers). The reports are collected through:
- VigiFlow: A web-based software provided by the WHO for global pharmacovigilance reporting, where India contributes its ADR reports to VigiBase, the WHO’s global ADR database.
- ADR Reporting Forms: Paper-based or electronic forms for submitting ADRs.
- Mobile Applications: The PvPI ADR Reporting App, launched to make it easier for healthcare professionals and patients to report ADRs directly from their smartphones.
The collected ADR reports are analyzed at the NCC, where trained pharmacovigilance professionals assess the severity, causality, and preventability of ADRs. Based on the analysis, PvPI may issue safety alerts and communicate risks to healthcare professionals and the public.
4. PvPI’s Achievements and Contributions
a) Enhancing Public Safety: PvPI has significantly enhanced drug safety in India by identifying and mitigating risks associated with drug use. It has successfully detected and acted upon several critical safety signals:
- Pioglitazone suspension: In 2013, PvPI identified the association between pioglitazone (an anti-diabetic drug) and an increased risk of bladder cancer. The drug was briefly suspended in India, and its use was restricted with new safety warnings.
- Oral sodium valproate: PvPI flagged risks associated with the use of sodium valproate during pregnancy, leading to birth defects. This led to regulatory actions for stronger warnings and guidelines on its use.
b) Collaborating with International Agencies: PvPI has actively collaborated with the WHO’s International Drug Monitoring Programme, contributing to VigiBase and ensuring that Indian pharmacovigilance data helps improve global drug safety.
c) Integration with Materiovigilance Program: In 2015, PvPI launched the Materiovigilance Program of India (MvPI), which aims to monitor adverse events related to the use of medical devices. This was a significant step in broadening the scope of PvPI beyond medicines to include medical devices, thereby promoting overall patient safety.
d) Capacity Building and Training: PvPI has organized numerous workshops, training programs, and conferences for healthcare professionals to build awareness and enhance the pharmacovigilance skills of healthcare providers across the country. This training ensures that professionals understand how to recognize and report ADRs, leading to more accurate and timely reporting.
5. Role of Healthcare Professionals in PvPI
Healthcare professionals play a crucial role in the success of PvPI. They are encouraged to report any suspected ADRs encountered in their clinical practice. The active involvement of healthcare professionals ensures that:
- Drug-related risks are identified early.
- Safety signals are detected before they cause widespread harm.
- Patients receive timely interventions to prevent or minimize harm from ADRs.
PvPI encourages healthcare professionals to report all types of ADRs, even minor or well-known side effects, to help build a comprehensive database of drug safety information.
6. Patient Involvement in Pharmacovigilance
PvPI has actively promoted the role of patients in pharmacovigilance. Patients can report ADRs directly through mobile apps or online forms. Encouraging patient reporting helps in:
- Capturing ADRs that may not be reported by healthcare providers.
- Understanding the real-world safety of medicines from the patient’s perspective.
- Building a patient-centric approach to pharmacovigilance, empowering individuals to contribute to the safety of the medicines they use.
7. Challenges Faced by PvPI
Despite its progress, PvPI faces several challenges:
- Underreporting of ADRs: One of the primary challenges is underreporting by healthcare professionals and patients. Lack of awareness, time constraints, and fear of legal repercussions contribute to this problem.
- Data quality: Ensuring the completeness and accuracy of ADR reports can be difficult, particularly in remote or resource-limited settings.
- Awareness: Although efforts have been made, raising awareness about the importance of pharmacovigilance among healthcare professionals and patients remains an ongoing challenge.
8. Future Directions for PvPI
a) Expanding Coverage: PvPI aims to expand its network of AMCs, particularly in rural and underserved areas, to ensure comprehensive coverage of ADR reporting across India. This expansion will help capture more ADRs from diverse populations.
b) Digital Health Integration: With the increasing use of electronic health records (EHRs) and digital health tools, PvPI plans to integrate its pharmacovigilance systems with EHRs and other digital platforms to enable automatic ADR reporting, reducing the burden on healthcare professionals.
c) Real-World Evidence and Big Data Analytics: PvPI is exploring the use of real-world evidence (RWE) and big data analytics to enhance its signal detection capabilities. By analyzing large datasets from various sources, PvPI can improve its ability to detect and respond to emerging safety signals.
Conclusion
The Pharmacovigilance Program of India (PvPI) plays a critical role in ensuring the safety of medicines in India. By monitoring ADRs, generating safety data, and collaborating with international organizations, PvPI has improved the safety profile of medicines used in India. Despite some challenges, PvPI continues to evolve by expanding its coverage, enhancing its digital infrastructure, and building awareness among healthcare professionals and patients. Its efforts are essential for protecting public health and ensuring that the medicines used in India are both safe and effective.
